JP7812232B2 - 癌患者における抗腫瘍免疫の増強のための患者選択 - Google Patents

癌患者における抗腫瘍免疫の増強のための患者選択

Info

Publication number
JP7812232B2
JP7812232B2 JP2021575320A JP2021575320A JP7812232B2 JP 7812232 B2 JP7812232 B2 JP 7812232B2 JP 2021575320 A JP2021575320 A JP 2021575320A JP 2021575320 A JP2021575320 A JP 2021575320A JP 7812232 B2 JP7812232 B2 JP 7812232B2
Authority
JP
Japan
Prior art keywords
patient
cancer
cdk4
inhibitor
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021575320A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022536854A5 (cg-RX-API-DMAC7.html
JP2022536854A (ja
Inventor
パトリック、ジョセフ、ロバーツ
アンヌ、ライ
ジェシカ、ソレンティノ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacosmos Holding AS
Original Assignee
Pharmacosmos Holding AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacosmos Holding AS filed Critical Pharmacosmos Holding AS
Publication of JP2022536854A publication Critical patent/JP2022536854A/ja
Publication of JP2022536854A5 publication Critical patent/JP2022536854A5/ja
Application granted granted Critical
Publication of JP7812232B2 publication Critical patent/JP7812232B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hospice & Palliative Care (AREA)
JP2021575320A 2019-06-18 2020-06-18 癌患者における抗腫瘍免疫の増強のための患者選択 Active JP7812232B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962863153P 2019-06-18 2019-06-18
US62/863,153 2019-06-18
US201962907375P 2019-09-27 2019-09-27
US62/907,375 2019-09-27
PCT/US2020/038557 WO2020257536A1 (en) 2019-06-18 2020-06-18 Patient selection for enhancement of anti-tumor immunity in cancer patients

Publications (3)

Publication Number Publication Date
JP2022536854A JP2022536854A (ja) 2022-08-19
JP2022536854A5 JP2022536854A5 (cg-RX-API-DMAC7.html) 2023-06-27
JP7812232B2 true JP7812232B2 (ja) 2026-02-09

Family

ID=74040931

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021575320A Active JP7812232B2 (ja) 2019-06-18 2020-06-18 癌患者における抗腫瘍免疫の増強のための患者選択

Country Status (9)

Country Link
US (1) US20220175787A1 (cg-RX-API-DMAC7.html)
EP (1) EP3986410A4 (cg-RX-API-DMAC7.html)
JP (1) JP7812232B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220024540A (cg-RX-API-DMAC7.html)
CN (1) CN114222577A (cg-RX-API-DMAC7.html)
AU (1) AU2020296087A1 (cg-RX-API-DMAC7.html)
CA (1) CA3143339A1 (cg-RX-API-DMAC7.html)
TW (1) TW202114684A (cg-RX-API-DMAC7.html)
WO (1) WO2020257536A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6430483B2 (ja) * 2013-03-15 2018-11-28 ジー1、セラピューティクス、インコーポレイテッドG1 Therapeutics, Inc. 化学療法の間の正常細胞の一時的な保護
IL317919A (en) 2016-12-05 2025-02-01 G1 Therapeutics Inc Preservation of immune response during chemotherapy regimens
JP7853532B2 (ja) 2020-05-19 2026-04-30 ファーマコスモス ホールディング エー/エス 医学的障害を治療するためのサイクリン依存性キナーゼ阻害化合物
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
US20240285634A1 (en) * 2021-06-10 2024-08-29 Onquality Pharmaceuticals China Ltd. Compound and method for treating chemotherapy-associated gastrointestinal side effects
CA3223467A1 (en) * 2021-07-01 2023-01-05 Andrew BEELEN Combination treatments in patients with advanced and/or metastatic trop-2 overexpressed cancers
US20250003986A1 (en) * 2021-10-14 2025-01-02 Wisconsin Alumni Research Foundation K17 as a biomarker for tumor response to immunotherapy
CN115019880B (zh) * 2022-05-05 2024-01-09 中山大学附属第一医院 一种肝癌预后模型及其构建方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014144326A1 (en) 2013-03-15 2014-09-18 G1 Therapeutics, Inc. Transient protection of normal cells during chemotherapy
WO2018106729A1 (en) 2016-12-05 2018-06-14 G1 Therapeutics, Inc. Preservation of immune response during chemotherapy regimens

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102186969B1 (ko) 2010-10-25 2020-12-04 쥐원 쎄라퓨틱스, 인크. Cdk 억제제
US10551379B2 (en) 2013-03-15 2020-02-04 President And Fellows Of Harvard College Methods and compositions for improving detection and/or capture of a target entity
US20160220569A1 (en) * 2015-02-03 2016-08-04 G1 Therapeutics, Inc. CDK4/6 Inhibitor Dosage Formulations For The Protection Of Hematopoietic Stem And Progenitor Cells During Chemotherapy
US11865176B2 (en) * 2016-11-08 2024-01-09 Dana-Farber Cancer Institute, Inc. Compositions and methods of modulating anti-tumor immunity
EP3585389A4 (en) * 2017-02-22 2020-12-23 G1 Therapeutics, Inc. EGFR-CAUSED CANCER TREATMENT WITH LESS SIDE EFFECTS
US20200377599A1 (en) * 2017-11-30 2020-12-03 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for treating cancer
US10122265B1 (en) 2018-01-03 2018-11-06 Intel Corporation Reducing electromagnetic interference in switching regulators
WO2023034336A2 (en) * 2021-08-30 2023-03-09 G1 Therapeutics, Inc. Improved treatments for advanced/metastatic cancers with checkpoint inhibitor resistance or resistance susceptibility

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014144326A1 (en) 2013-03-15 2014-09-18 G1 Therapeutics, Inc. Transient protection of normal cells during chemotherapy
WO2018106729A1 (en) 2016-12-05 2018-06-14 G1 Therapeutics, Inc. Preservation of immune response during chemotherapy regimens

Also Published As

Publication number Publication date
KR20220024540A (ko) 2022-03-03
AU2020296087A1 (en) 2022-01-27
JP2022536854A (ja) 2022-08-19
WO2020257536A1 (en) 2020-12-24
CN114222577A (zh) 2022-03-22
US20220175787A1 (en) 2022-06-09
CA3143339A1 (en) 2020-12-24
EP3986410A1 (en) 2022-04-27
EP3986410A4 (en) 2023-06-28
TW202114684A (zh) 2021-04-16

Similar Documents

Publication Publication Date Title
US20220175787A1 (en) Patient selection for enhancement of anti-tumor immunity in cancer patients
Maron et al. Targeted therapies for targeted populations: anti-EGFR treatment for EGFR-amplified gastroesophageal adenocarcinoma
US20230115328A1 (en) Anti-B7-H1 and Anti-CTLA-4 Antibodies for Treating Non-Small Cell Lung Cancer
Hirano et al. Systemic treatment of advanced esophageal squamous cell carcinoma: chemotherapy, molecular-targeting therapy and immunotherapy
JP7458188B2 (ja) 腫瘍を処置する方法
Floudas et al. A pilot study of the PD-1 targeting agent AMP-224 used with low-dose cyclophosphamide and stereotactic body radiation therapy in patients with metastatic colorectal cancer
KR102644408B1 (ko) 암의 치료를 위한 항-pd-l1 항체 및 dna-pk 억제제의 병용
JP7089507B2 (ja) Pd-1軸阻害剤への応答を予測すること
JP2025148465A (ja) 腫瘍の処置方法
KR20240029045A (ko) 진행성 및/또는 전이성 Trop-2 과다발현 암을 갖는 환자에서의 조합 치료
JP2022504468A (ja) 転移性膵臓腺癌の処置
WO2022087018A1 (en) Improved fluorouracil-based multi-agent chemotherapy for treatment of metastatic colorectal cancer
CN111225673A (zh) 亚德阿霉素组合治疗及方法
Xu et al. Pharmacological strategies to overcome immune checkpoint inhibitor resistance in non-small cell lung cancer
WO2024196952A1 (en) Tumor subtype assessment for cancer therapy
HK40066320A (en) Patient selection for enhancement of anti-tumor immunity in cancer patients
TW202237127A (zh) 患有進行性及/或轉移性疾病之難治療三陰性乳癌患者之改良治療
TW202228772A (zh) 藉由併用阿替利珠單抗、托珠單抗、吉西他濱、白蛋白結合紫杉醇之4劑的胰臟癌治療劑
Guan¹ et al. refractory bullous pemphigoid induced by immune checkpoint
HK40121936A (en) Methods of treating pancreatic cancer with a pd-1 axis binding antagonist and an rna vaccine
HK40013014A (en) Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small cell lung cancer
HK40066138A (en) Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 insertions
HK1235023A1 (en) Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small cell lung cancer
HK1235023B (en) Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small cell lung cancer

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20230619

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230619

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240903

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241128

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250115

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250522

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250617

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250903

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20251014

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20251014

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251216

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260109

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260128

R150 Certificate of patent or registration of utility model

Ref document number: 7812232

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150